

PATENT

Docket No.: 20747/270 (ARDBW/P29257US)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Axel Andreas THOMSON	)
		)
U. S. Serial No:	To be assigned	)
		)
Filed:	Herewith	)
		)
PCT International Application No:	PCT/GB2003/004117	)
		)
Filed:	17 September 2003	)
		)
For :	A METHOD OF PROTECTING A	)
	PATIENT FROM POSSIBLE	)
	ADVERSE EFFECTS OF INHIBITION	)
	OF THE SHH-SIGNALLING	)
	PATHWAY BY SUPPRESSING	)
	TESTOSTERONE OR ITS EFFECTS	)
	IN THE PATIENT	)

---

## INFORMATION DISCLOSURE STATEMENT

**Mail Stop: PCT**  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. 1.56, 1.97, and 1.98, published art included in the International Search Report (copy enclosed) of the corresponding PCT application, is cited for consideration and listed on the enclosed PTO-1449 form as references 1-3. These references are relevant for the reasons given in the search report.

Because copies of the references 1-3 should have been transferred by the International Searching Authority ("ISA"), duplicate copies are not enclosed herewith. Should the U.S. Patent and Trademark Office ("PTO") require copies of references 1-3 from

applicants (i.e., the ISA has not provided them), the PTO should contact the undersigned representative directly.

It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

Date: March 17, 2005



Edwin V. Merkel  
Registration No. 40,087

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1128  
Facsimile: (585) 263-1600

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	To Be Assigned
				Filing Date	Herewith
				First Named Inventor	Axel Andreas Thomson
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	20747/270 (ARDBW/P29257US)

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Berman et al., "Medulloblastoma growth inhibition by Hedgehog pathway blockade", <u>Science</u> , 297(5586):1559-1561 (2002).	
	2	Podlasek et al., "Prostate development requires Sonic hedgehog expressed by the urogenital sinus epithelium", <u>Developmental Biology</u> , 209 (1):28-39 (1999).	
	3.	Bergman et al., "Inhibition of prostate morphogenesis by the sonic hedgehog pathway inhibitor cyclopamine", <u>Journal of Urology</u> , 163(4 suppl.):204 (2000).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.